NewAmsterdam Pharma Files 20-F/A Amendment

TL;DR

NAMS filed an amendment for its 2022 20-F, updating corporate and financial details.

AI Summary

NewAmsterdam Pharma Co N.V. filed an amendment (20-F/A) on October 28, 2024, for its fiscal year ending December 31, 2022. The filing details its organizational structure, including various share classes and financing events like a PIPE Financing Member in 2022. The company was formerly known as NewAmsterdam Pharma Co B.V. before a name change on July 1, 2022.

Why It Matters

This amendment provides updated financial and corporate information for NewAmsterdam Pharma Co N.V., crucial for investors and analysts tracking the company's status and historical financial reporting.

Risk Assessment

Risk Level: low — The filing is an amendment to a previous report, primarily containing updated corporate and financial information rather than new material events.

Key Numbers

• 20221231 — Fiscal Year End (The period for which the 20-F/A amendment is filed.)
• 20241028 — Filing Date (The date the amendment was submitted to the SEC.)

Key Players & Entities

• NewAmsterdam Pharma Co N.V. (company) — Filer of the 20-F/A amendment
• NewAmsterdam Pharma Co B.V. (company) — Former name of the company
• 20221231 (date) — Conformed period of report
• 20241028 (date) — Filing date
• PIPE Financing Member (financial_event) — A type of financing mentioned for the period 2022-01-01 to 2022-12-31

FAQ

Filing Documents

• nams-20221231.htm (20-F/A) — 4764KB
• nams-ex2_4.htm (EX-2.4) — 110KB
• nams-ex12_1.htm (EX-12.1) — 15KB
• nams-ex12_2.htm (EX-12.2) — 15KB
• nams-ex13_1.htm (EX-13.1) — 9KB
• nams-ex13_2.htm (EX-13.2) — 8KB
• img30326675_0.jpg (GRAPHIC) — 146KB
• img106017521_0.jpg (GRAPHIC) — 158KB
• img106017521_1.jpg (GRAPHIC) — 652KB
• img106017521_2.jpg (GRAPHIC) — 655KB
• img106017521_3.jpg (GRAPHIC) — 755KB
• img106017521_4.jpg (GRAPHIC) — 670KB
• img106017521_5.jpg (GRAPHIC) — 81KB
• img106017521_6.jpg (GRAPHIC) — 75KB
• img106017521_7.jpg (GRAPHIC) — 72KB
• img106017521_8.jpg (GRAPHIC) — 2KB
• img106017521_9.jpg (GRAPHIC) — 114KB
• img106017521_10.jpg (GRAPHIC) — 100KB
• img106017521_11.jpg (GRAPHIC) — 52KB
• img106017521_12.jpg (GRAPHIC) — 567KB
• 0000950170-24-117574.txt ( ) — 26722KB
• nams-20221231.xsd (EX-101.SCH) — 1822KB
• nams-20221231_htm.xml (XML) — 3756KB

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 152 ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 154 A. DEBT SECURITIES 154 B. WARRANTS AND RIGHTS 154 C. OTHER SECURITIES 154 D. AMERICAN DEPOSITORY SHARES 154 PART II 155 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 155 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 155 ITEM 15.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 155 ITEM 16. [RESERVED] 156 A. AUDIT COMMITTEE FINANCIAL EXPERT 156 B. CODE OF ETHICS 156 C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 156 D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 157 E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 157 F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 157 G. CORPORATE GOVERNANCE 157 H. MINE SAFETY DISCLOSURE 158 I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 158 PART III 159 ITEM 17.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 159 ITEM 18.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 159 5 ITEM 19. EXHIBITS 159 MARKET AND INDUSTRY DATA This Annual Report contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. These data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. We caution you not to give undue weight to such projections, assumptions and estimates. GENERAL INFORMATION Unless otherwise stated or the context otherwise indicates, (i) references to "we," "our," "us," "Holdco" or the "Company" refer to NewAmsterdam Pharma Company N.V. (f/k/a NewAmsterdam Pharma Company B.V.), together with its subsidiaries and (ii) references to "NewAmsterdam Pharma" refer solely to NewAmsterdam Pharma Holding B.V., a private company with limited liability ( besloten vennootschap met beperkte aansprakelijkheid ) incorporated under the laws of the Netherlands and its subsidiaries. Our financial statements have been prepared in accordance with International Financial Reporting Standards (as issued by the International Accounting Standards Board ("IFRS") and our consolidated financial statements are presented in Euros. Unless otherwise indicated, all references in this Annual Report to "," "euro," "EUR" or "cents" are to Euros. All references to "$" are to U.S. dollars. SERVICE MARKS AND TRADE NAMES The NewAmsterdam Pharma name, logos and other service marks of NewAmsterdam Pharma appearing in this Annual Report are the property of NewAmsterdam Pharma. Solely for convenience, some

IDENTIT Y OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

ITEM 1. IDENTIT Y OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Not applicable.

OFFER STATISTICS AND EXPECTED TIMETABLE

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE Not applicable.

KEY INFORMATION

ITEM 3. KEY INFORMATION A. [Reser ved] B. CAPITALIZ ATION AND INDEBTEDNESS Not applicable. C. REASONS FOR TH E OFFER AND USE OF PROCEEDS Not applicable. D. RISK F ACTORS You should carefully consider the following risk factors, together with all of the other information included in this Annual Report, before making an investment in our ordinary shares, nominal value 0.12 per share (our "Ordinary Shares"). These risk factors are not exhaustive and investors are encouraged to perform their own investigation with respect to our business, financial condition and prospects . The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on the business, cash flows, financial condition and results of operations of the Company. The risks discussed below may not prove to be exhaustive and are based on certain assumptions made by the Company which later may prove to be incorrect or incomplete. We may face additional risks and uncertainties that are not presently known to us, or that are currently deemed immaterial, which may also impair our business or financial condition. You should carefully read and consider the matters discussed in this section of the Annual Report, which include the following risks: We are a clinical-stage company with limited operating history, no approved products and no historical product revenues, which makes it difficult to assess our future prospects and financial results. We have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any product revenue or become profitable or, if we achieve profitability, may not be able to sustain it. We are dependent on the success of our only product candidate, obicetrapib, and cannot guarantee that obicetrapib will successfully complete clinical development, receive

View Full Filing

View this 20-F/A filing on SEC EDGAR